538
Participants
Start Date
April 30, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
851B
851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
851B
851B 3.0% formulation, gel, topically, once a week for 1 cycle.
851B
851B 3.0% formulation, gel, topically, once a week for 2 cycles.
851B
851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
851B
851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
851B
851B placebo-matching gel, topically, once a week for 1 cycle.
851B
851B placebo-matching gel, topically, twice a week for 1 cycle.
851B
851B placebo-matching gel, topically, once a week for 2 cycles.
851B
851B placebo-matching gel, topically, twice a week for 2 cycles.
Birmingham
Enterprise
Huntsville
Montgomery
Chandler
Phoenix
Tucson
Jonesboro
Carmichael
Colton
San Diego
San Francisco
Santa Rosa
Colorado Springs
Longmont
Louisville
Danbury
Groton
Aventura
Boynton Beach
Clearwater
Fort Myers
Leesburg
Miami
Pembroke Pines
Plantation
Tampa
West Palm Beach
Atlanta
Augusta
Decatur
Savannah
Woodstock
Boise
Idaho Falls
Evansville
Des Moines
Iowa City
Louisville
Marrero
Metairie
Detroit
Paw Paw
Chaska
St Louis
Las Vegas
Reno
Lebanon
Newark
Albuquerque
New York
The Bronx
Chapel Hill
Charlotte
Durham
New Bern
Winston-Salem
Bismarck
Fargo
Gallipolis
Oklahoma City
Eugene
Medford
Erie
Philadelphia
Pittsburgh
Pottstown
West Reading
Wynnewood
Columbia
Greenville
Watertown
Bristol
Chattanooga
Clarksville
Memphis
Nashville
Austin
Carrollton
Dallas
Houston
Plano
San Antonio
Sandy City
Richmond
Virginia Beach
Renton
Seattle
Winnipeg
Ottawa
Québec
Toronto
Rio Piedras
Lead Sponsor
Takeda
INDUSTRY